Vita 34 becomes market leader in Austria

Vita 34 AG  / Key word(s): Acquisition

01.12.2014 18:24

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Vita 34 becomes market leader in Austria

Leipzig, 1 December 2014 - Vita 34 AG (WKN A0BL84) takes over the
commercial operations of the Austrian market leader for umbilical cord
blood storages as of January 2, 2015 within the framework of an asset deal.

Today, the board of directors signed the purchase agreement to take over
all the assets of Vivocell Biosolutions GmbH & Co KG from Graz at a price
of 650,000 Euro upon approval by the supervisory board.

The 13,000 stored preparations that were taken over will be taken care of
in the future by the Austrian subsidiary of Vita 34 AG. There will be no
transfer of Vivocell's employees to Vita 34.

The group revenue of Vita 34 will increase in 2015 by about seven percent
because of the takeover.

Additional information:
ISIN: DE000A0BL849
Ticker symbol: V3V
Market segment: Regulated Market (Prime Standard) of the Frankfurt Stock

Vita 34 AG
Deutscher Platz 5
04103 Leipzig


01.12.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at and

Language:     English
Company:      Vita 34 AG
              Deutscher Platz 5a
              04103 Leipzig
Phone:        +49(0341)48792-40
Fax:          +49(0341)48792-39
ISIN:         DE000A0BL849
WKN:          A0BL84
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of Announcement                             DGAP News-Service